[Progressive supranuclear palsy, diagnostic problems in the light of own case].
A case is reported in which the neurological findings and disease course meet fully the criteria of the possible progressive supranuclear palsy. The authors discuss the principles of clinical diagnosis of the syndrome, characteristic oculomotor disturbances and parkinsonian syndrome especially pronounced in this disease in the muscles of the nape, trunk and upper extremities. The main features of neuropathological changes are described fibrillary degeneration and atrophy of neurons in midbrain and pons, with accumulation of tau protein in the neurons and astrocytes in the areas involved by the process.
Kulczycki
J
J
I Kliniki Neurologicznej, Instytutu Psychiatrii i Neurologii w Warszawie.
Kuran
W
W
D001253:Astrocytes / Q000737:chemistry; D001284:Atrophy / Q000473:pathology; D001418:Baclofen / Q000627:therapeutic use; D001545:Benserazide / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000188:drug therapy / Q000209:etiology; D004338:Drug Combinations; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D018755:GABA Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009388:Neostigmine / Q000627:therapeutic use; D009474:Neurons / Q000737:chemistry; D015835:Ocular Motility Disorders / Q000150:complications; D012720:Severity of Illness Index; D013494:Supranuclear Palsy, Progressive / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D016875:tau Proteins / Q000032:analysis
D002800:Cholinesterase Inhibitors; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D018755:GABA Agonists; C005177:benserazide, levodopa drug combination; D016875:tau Proteins; D009388:Neostigmine; D007980:Levodopa; D001545:Benserazide; D001418:Baclofen